Published in Br J Haematol on August 30, 2013
A Comprehensive Gene Expression Meta-analysis Identifies Novel Immune Signatures in Rheumatoid Arthritis Patients. Front Immunol (2017) 0.75
Identification of human leukemia antigen A*0201-restricted epitopes derived from epidermal growth factor pathway substrate number 8. Mol Med Rep (2015) 0.75
Three-way interaction model to trace the mechanisms involved in Alzheimer's disease transgenic mice. PLoS One (2017) 0.75
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood (1997) 4.97
More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov (2007) 2.68
CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest (1997) 2.39
Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research. BMC Immunol (2008) 2.30
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med (2007) 1.73
Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol (2007) 1.69
Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med (2001) 1.50
The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res (2001) 1.50
Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results. Neoplasma (2012) 1.49
Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules. J Immunol (1996) 1.40
Multiple myeloma. Annu Rev Med (2011) 1.33
Right place, right time, right peptide: DO keeps DM focused. Immunol Rev (2005) 1.30
Identification of T-cell epitopes for cancer immunotherapy. Leukemia (2007) 1.23
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood (2010) 1.20
Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Clin Cancer Res (2011) 1.19
The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol Immunother (2004) 1.09
Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice. Gene Ther (2006) 1.08
WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol (2008) 1.04
Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood (2002) 1.03
Immune responses to the HLA-A*0201-restricted epitopes of tyrosinase and glycoprotein 100 enable control of melanoma outgrowth in HLA-A*0201-transgenic mice. J Immunol (2001) 1.00
A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers. J Biol Chem (2010) 1.00
Multiple myeloma - current issues and controversies. Cancer Treat Rev (2010) 0.99
Molecular detection of targeted major histocompatibility complex I-bound peptides using a probabilistic measure and nanospray MS3 on a hybrid quadrupole-linear ion trap. Anal Chem (2010) 0.96
Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients. Br J Haematol (2010) 0.95
A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma. Br J Haematol (2012) 0.93
Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma. Blood (2005) 0.92
Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells. J Immunother (2011) 0.90
Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders. Br J Haematol (2011) 0.90
MHC class II molecules in tumour immunology: prognostic marker and target for immune modulation. Immunobiology (2006) 0.89
Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein. Immunology (2002) 0.85
Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients. Clin Exp Immunol (2005) 0.85
Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTL. J Immunol (2005) 0.83
Immune therapies. Hematol Oncol Clin North Am (2007) 0.81
The HLA-DOB gene displays limited polymorphism with only one amino acid substitution. Tissue Antigens (2002) 0.80
Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells. Cancer Immunol Immunother (2011) 0.78
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics (2006) 22.61
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Gene regulation and DNA damage in the ageing human brain. Nature (2004) 9.01
An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics (2004) 6.78
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 6.24
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer (2007) 5.57
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem (2002) 4.94
Multiple myeloma. Lancet (2009) 4.60
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 4.56
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood (2010) 4.52
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A (2003) 4.47
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 4.46
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science (2013) 4.39
Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A (2002) 4.33
Advances in biology of multiple myeloma: clinical applications. Blood (2004) 4.13
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med (2010) 4.00
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A (2005) 3.86
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell (2007) 3.76
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood (2002) 3.73
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood (2002) 3.62
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol (2005) 3.43
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell (2005) 3.41
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood (2006) 3.39
Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput Biol (2006) 3.39
Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. Nucleic Acids Res (2004) 3.37
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37
ChipInfo: Software for extracting gene annotation and gene ontology information for microarray analysis. Nucleic Acids Res (2003) 3.31
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A (2003) 3.30
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell (2004) 3.25
Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol (2009) 3.21
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol (2006) 3.20
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood (2009) 3.12
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood (2006) 3.04
HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity (2008) 3.01
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood (2002) 3.01
A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet (2005) 2.85
Allele-specific amplification in cancer revealed by SNP array analysis. PLoS Comput Biol (2005) 2.84
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res (2002) 2.83
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood (2007) 2.76
Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med (2006) 2.72
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene (2002) 2.66
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood (2007) 2.65
Pharmaceutical supply chain in China: current issues and implications for health system reform. Health Policy (2010) 2.63
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood (2009) 2.61
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol (2009) 2.59
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol (2010) 2.51
Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles. Immunogenetics (2004) 2.49
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol (2008) 2.45
Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood (2006) 2.43
Prediction of MHC class I binding peptides using profile motifs. Hum Immunol (2002) 2.43
Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer (2002) 2.42
The alphabeta T cell receptor is an anisotropic mechanosensor. J Biol Chem (2009) 2.41
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica (2006) 2.40
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med (2015) 2.39
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest (2013) 2.34
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol (2009) 2.32
Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research. BMC Immunol (2008) 2.30
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood (2012) 2.29
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood (2009) 2.28
Utilization of a whole genome SNP panel for efficient genetic mapping in the mouse. Genome Res (2006) 2.26
Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol (2012) 2.25
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res (2009) 2.25
Antimyeloma activity of heat shock protein-90 inhibition. Blood (2005) 2.24
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood (2003) 2.23
Evolution of the aging brain transcriptome and synaptic regulation. PLoS One (2008) 2.23
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood (2003) 2.22
Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol (2008) 2.21
Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients. Leuk Lymphoma (2010) 2.20
Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research. BMC Bioinformatics (2008) 2.17